C. Brandt, P. Seja, K. Töllner, K. Römermann, P. Hampel, M. Kalesse, A. Kipper, P. W. Feit, K. Lykke, T. L. Toft-Bertelsen, P. Paavilainen, I. Spoljaric, M. Puskarjov, N. MacAulay, K. Kaila, W. Löscher (2018): “Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti-seizure efficacy” Neuropharmacology; 143:186-204.

 

C. Brandt, P. Hillmann, A. Noack, K. Römermann, L. A. Öhler, D. Rageot, F. Beaufils, A. Melone, A. M. Sele, M. P. Wymann, D. Fabbro, W. Löscher (2018): “The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy” Neuropharmacology; 140:107-20.

 

P. Hampel*, K. Römermann*, N. MacAulay, W. Löscher (2018): “Azosemide is more potent than bumetanide and various other loop diuretics to inhibit the sodium-potassium-chloride-cotransporter human variants hNKCC1A and hNKCC1B” Scientific Reports; 8:9877 [10.1038/s41598-018-27995-w].

 

A. Schidlitzki, F. Twele, R. Klee, I. Waltl, K. Römermann, S. Bröer, S. Meller, I. Gerhauser, V. Rankovic, D. Li, C. Brandt, M. Bankstahl, K. Töllner, W. Löscher (2017): “A combination of NMDA and AMPA receptor antagonists retards granule cell dispersion and epileptogenesis in a model of acquired epilepsy” Scientific Reports; 7:12191 [DOI:10.1038/s41598-017-12368-6].

 

K. Römermann, M. Fedrowitz, P. Hampel, E. Kaczmarek, K. Töllner, T. Erker, D. H. Sweet, W. Löscher (2017): "Multiple blood-brain barrier transport mechanisms limit bumetanide accumulation, and therapeutic potential, in the mammalian brain” Neuropharmacology; 117:182-194.

 

M. Bankstahl, S. Klein, K. Römermann, W. Löscher (2016): “Knockout of P-glycoprotein does not alter antiepileptic drug efficacy in the intrahippocampal kainate model of mesial temporal lobe epilepsy in mice” Neuropharmacology; 109:183-95.

 

M. Bauer, K. Römermann, R. Karch, B. Wulkersdorfer, J. Stanek, C. Philippe, A. Maier-Salamon, H. Haslacher, C. Jungbauer, W. Wadsak, W. Jäger, W. Löscher, M. Hacker, M. Zeitlinger, O. Langer (2016): “Pilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Blood-Brain Barrier” Clin Pharmacol Ther.; 100(2):131-41.

 

T. Wanek, E. Halilbasic, M Visentin, S. Mairinger, K. Römermann, B. Stieger, C. Kuntner, M. Müller, O. Langer, M. Trauner (2016): „Influence of 24-Nor-Ursodeoxycholic Acid on Hepatic Disposition of [(18)F]Ciprofloxacin, a Positron Emission Tomography Study in Mice” J Pharm Sci.; 105(1):106-12.

 

R. Klee, K. Töllner, V. Rankovic, K. Römermann, A. Schidlitzki, M. Bankstahl, W. Löscher (2015): „Network pharmacology for antiepileptogenesis: Tolerability of multitargeted drug combinations in nonepileptic vs. post-status epilepticus mice” Epilepsy Res.; 118:34-48.

 

T. Wanek, K. Römermann, S. Mairinger, J. Stanek, M. Sauberer, T. Filip, A. Traxl, C. Kuntner, J. Pahnke, F. Bauer, T. Erker, W. Löscher, M. Müller, O. Langer (2015): „Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography” Mol Pharm.; 12(9):3214-25.

 

K. Lykke, K. Töllner, K. Römermann, P. W. Feit, T. Erker, N. MacAulay, W. Löscher (2015): „Structure-activity relationships of bumetanide derivatives: correlation between diuretic activity in dogs and inhibition of the human NKCC2A transporter” Br J Pharmacol.; 172(18):4469-80.

 

F. Twele, M. Bankstahl, S. Klein, K. Römermann, W. Löscher (2015): „The AMPA receptor antagonist NBQX exerts anti-seizure but not antiepileptogenic effects in the intrahippocampal kainate mouse model of mesial temporal lobe epilepsy” Neuropharmacology; 95:234-42.

 

K. Römermann, R. Helmer, W. Löscher (2015): „The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2)” Neuropharmacology; 93:7-14.

 

M. Bauer, R. Karch, M. Zeitlinger, C. Philippe, K. Römermann, J. Stanek, A. Maier-Salamon, W. Wadsak, W. Jäger, M. Hacker, M. Müller, O. Langer (2015): „Approaching complete inhibition of P-glycoprotein at the human blood-brain barrier: an (R)-[11C]verapamil PET study” J Cereb Blood Flow Metab.; 35(5):743-6.

 

K. Römermann, J. P. Bankstahl, W. Löscher, M. Bankstahl (2015): „Pilocarpine-induced convulsive activity is limited by multidrug transporters at the rodent blood-brain barrier” J Pharmacol Exp Ther.; 353(2):351-9.

 

K. Töllner, C. Brandt, K. Römermann, W. Löscher (2015): „The organic anion transport inhibitor probenecid increases brain concentrations of the NKCC1 inhibitor bumetanide” Eur J Pharmacol.; 746:167-73.

 

D. Alms, M. Fedrowitz, K. Römermann, A. Noack, W. Löscher (2014): “Marked differences in the effect of antiepileptic and cytostatic drugs on the functionality of P-glycoprotein in human and rat brain capillary endothelial cell lines” Pharm Res.; 31(6):1588-604.

 

A. Noack, S. Noack, A. Hoffmann, K. Maalouf, M. Buettner, P. O. Couraud, I. A. Romero, B. Weksler, D. Alms, K. Römermann, H. Y. Naim, W. Löscher (2014): “Drug-induced trafficking of p-glycoprotein in human brain capillary endothelial cells as demonstrated by exposure to mitomycin C” PLoS One; 9(2):e88154.

 

K. Römermann*, T. Wanek*, M. Bankstahl, J. P. Bankstahl, M. Fedrowitz, M. Müller, W. Löscher, C. Kuntner, O. Langer (2013): „(R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP” Nucl Med Biol.; 40(7):873-8.

 

J. P. Bankstahl, M. Bankstahl, K. Römermann, T. Wanek, J. Stanek, A. D. Windhorst, M. Fedrowitz, T. Erker, M. Müller, W. Löscher, O. Langer, C. Kuntner (2013): „Tariquidar and elacridar are dose-dependently transported by P-glycoprotein and Bcrp at the blood-brain barrier: a small-animal positron emission tomography and in vitro study” Drug Metab Dispos.; 41(4):754-62.

 

S. Mairinger, J. P. Bankstahl, C. Kuntner, K. Römermann, M. Bankstahl, T. Wanek, J. Stanek, W. Löscher, M. Müller, T. Erker, O. Langer (2012): „The antiepileptic drug mephobarbital is not transported by P-glycoprotein or multidrug resistance protein 1 at the blood-brain barrier: A positron emission tomography study” Epilepsy Res.; 100(1-2):93-103.

 

W. Löscher, C. Luna-Tortós, K. Römermann, M. Fedrowitz (2011): “Do ATP-binding cassette transporters cause pharmacoresistance in epilepsy? Problems and approaches in determining which antiepileptic drugs are affected” Curr Pharm Des.; 17(26):2808-28.